Business EconomyPosted at: Dec 13 2025 4:02AM


Ozempic ® - world’s most prescribed GLP-1is now available in India

Hyderabad, Dec 12 (UNI) Novo Nordisk, a global healthcare company, on Friday announced the launch of its once-weekly diabetes drug Ozempic® (injectable semaglutide) in India, marking a significant addition to the country’s treatment options for type 2 diabetes.
The therapy, a GLP-1 receptor agonist, is approved as an adjunct to diet and exercise for adults with uncontrolled type 2 diabetes mellitus (T2DM).
The introduction of Ozempic® comes at a critical time for India, which, according to WHO’s 2023–24 estimates, has 101 million people living with diabetes—about 11.4% of the population—along with 136 million individuals with prediabetes and 254 million with generalised obesity, the Denmark based healthcare company said in a release here.
The growing metabolic health burden has heightened the need for effective and evidence-based interventions.
Ozempic® has shown strong clinical outcomes, including substantial reductions in HbA1c levels and notable weight-loss benefits. It is suitable for adults with HbA1c levels of 7% or higher, including those with elevated cardiovascular risk or existing cardiovascular disease.
Clinical evidence also indicates a reduction in cardiovascular events and protection against the progression of chronic kidney disease, making the drug a comprehensive option for long-term diabetes management.
Calling the launch a major milestone, Vikrant Shrotriya, Managing Director of Novo Nordisk India, said the therapy brings global clinical trust and proven performance to Indian patients.
He emphasized that the once-weekly delivery through an easy-to-use pen device offers meaningful improvements in glycaemic control, weight management and cardiovascular and kidney outcomes.
Ozempic® works by mimicking the action of the natural hormone GLP-1, helping regulate blood sugar, reduce appetite and support weight loss in people with type 2 diabetes.
With a long-standing global safety profile and more than 38 million patient-years of clinical use, semaglutide was recently added to the World Health Organisation’s Model List of Essential Medicines, underscoring its growing importance in diabetes and obesity care.
The drug is now available in India in 0.25 mg, 0.5 mg and 1 mg strengths via the FlexTouch® pen, enabling doctors to tailor dosing to each patient’s needs for effective, sustained diabetes control.
Ozempic® is a GLP-1 receptor agonist that helps: Improve glycaemic control and reduce HbA1c; Regulate appetite and food intake by acting on areas of the brain that control hunger besides supporting weight loss in people with T2DM.
The use of this medication is strictly contingent upon a licensed healthcare provider’s prescription and clinical judgment.
Always consult your healthcare professional for medical advice and treatment options tailored to your individual needs, it said.
UNI KNR RN
Please log in to get detailed story.
Tags: #Ozempic ® - world’s most prescribed GLP-1is now available in India
More News

Godrej incorporates subsidiary to enhance financial services presence

14 Jan 2026 | 8:03 PM

Mumbai, Jan 14 (UNI) Godrej Industries Ltd (GIL) has officially announced that it has incorporated a new subsidiary, called Godrej Investment Ltd, as its financial services arm, which will serve as an umbrella holding company for all group financial operations, including its lending businesses.

see more..

Large-Ticket Deals Power Industrial & Warehousing Leasing to 36 9 Mn Sq Ft in 2025: Colliers

14 Jan 2026 | 7:59 PM

Hyderabad, Jan 14( UNI) India’s industrial and warehousing real estate market recorded its strongest performance in recent years, with 36.9 million sq ft of leasing in 2025, registering a 16% year-on-year growth, according to a report released by Colliers India.

see more..

14 Jan 2026 | 7:35 PM

Hyderabad, Jan 14 UNI) : Capital inflows into India’s real estate sector rose sharply in calendar year 2025, reaching an all-time high of USD 14.3 billion, marking a 25 per cent year-on-year growth, according to a latest report ‘ India market Monitor Q4 2025- Investments’ released by CBRE South Asias Pvt Ltd.

see more..

Cyient founder Mohan Reddy receives living leged award by Geospatial World

14 Jan 2026 | 7:18 PM

Hyderabad, Jan 14 (UNI) Cyient, a global Intelligent Engineering solutions company, on Wednesday announced that its Founder Chairman, Dr. B.V.R. Mohan Reddy, has been conferred the ‘Living Legend Award’ by Geospatial World, one of the world’s leading geospatial knowledge organisations.

see more..

Dr Reddy’s launches first to market OTC antihistamine eye drop in US

14 Jan 2026 | 6:54 PM

Hyderabad, Jan 14 (UNI) : Dr. Reddy’s Laboratories on Wednesday announced the first-to-market U.S. launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the generic equivalent of Extra-Strength Pataday® Once-Daily Relief, following approval by the U.S. Food and Drug Administration.

see more..